SCHEDULE 13G/A: Investment Funds and Managing Member Disclose 7.9% Passive Stake in Imunon, Inc.

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have jointly disclosed a 7.9% beneficial ownership stake in Imunon, Inc., primarily through warrants.

Summary

• Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri (collectively, "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Imunon, Inc.
• As of December 31, 2024, each Reporting Person beneficially owns 1,250,000 shares of Imunon, Inc. Common Stock.
• This ownership represents 7.9% of the Issuer's Common Stock class.
• The reported shares are issuable upon the exercise of certain warrants held by the Reporting Persons.
• The shares are subject to a 9.99% beneficial ownership blocker.
• The percentage is calculated based on 14,500,685 shares of Common Stock outstanding as of November 5, 2024, as stated in Imunon's Form 10-Q filed on November 7, 2024.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Imunon, Inc.

Sentiment

Score: 6

Explanation: The document is a routine ownership disclosure. The presence of a significant institutional investor is generally positive, indicating confidence, but it provides no new operational or financial news from the company itself.

Positives

• Significant institutional investment (7.9%) by Ayrton Capital LLC and Alto Opportunity Master Fund, SPC, indicating confidence in Imunon, Inc.
• The investment is passive, suggesting no immediate intent to disrupt current management or operations.

Risks

• The beneficial ownership is primarily through warrants, which means the actual shares are not yet outstanding and their exercise is subject to a 9.99% beneficial ownership blocker.
• Potential dilution for existing shareholders if the warrants are exercised and the shares are issued, increasing the total outstanding share count.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from Imunon, Inc. or the reporting persons regarding future operations or financial performance, beyond the passive nature of the investment.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This filing indicates a significant passive investment by institutional funds in Imunon, Inc., a biotechnology or pharmaceutical company (implied by 'Imunon'). Such investments are common in the biotech sector, where specialized funds often take positions in companies with promising pipelines or technologies. The passive nature suggests the investors are not seeking to actively influence the company's strategic direction at this time, which is typical for Schedule 13G filers.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily reports a change in beneficial ownership and does not provide financial or operational results for comparison. Therefore, a direct comparison to industry standards for company performance is not applicable.
• However, institutional ownership of 7.9% is a notable stake, aligning with typical investment patterns where funds accumulate significant, yet passive, positions in companies they believe have long-term potential.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by institutional investors may be viewed positively, potentially signaling confidence in the company. However, the future exercise of warrants could lead to dilution.
• Management: The passive nature of the investment suggests no immediate pressure or intent to influence control from these specific investors.

Next Steps

• Imunon, Inc. shareholders may monitor future filings from these reporting persons for any changes in their ownership stake or a shift from passive to active investment (e.g., a Schedule 13D filing).
• Investors may also monitor Imunon, Inc.'s future financial reports for updates on its operations and the potential exercise of these warrants.

Key Dates

Keywords

Imunon Inc, IMUN, Schedule 13G, Beneficial Ownership, Ayrton Capital LLC, Alto Opportunity Master Fund, Waqas Khatri, Warrants, Institutional Investment, Passive Investment, SEC Filing